Ipsen Aktie

128,90 EUR +1,70 EUR +1,34 %

11:46:53

STU

120,20 CHF +1,85 CHF +1,56 %

11:57:33

BRX

Ipsen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.10,54 Mrd. EUR

KGV26,49Div. Rendite1,26%

WKNA0ESMG

ISINFR0010259150

SymbolIPSEF

Ipsen Aktien News

Sortieren:Datum Meistgelesen

25.07.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2023

24.07.23GlobeNewswireIpsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023

21.07.23GlobeNewswireIpsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome

19.07.23GlobeNewswireIpsen announces European Commission decision on palovarotene for the treatment of FOP

18.07.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023

11.07.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2023

10.07.23GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

10.07.23GlobeNewswireIpsen – Half year statement – 2023 06 30

04.07.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2023

30.06.23GlobeNewswireIpsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

29.06.23GlobeNewswireIpsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva

27.06.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2023

20.06.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2023

14.06.23GlobeNewswireIpsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma

13.06.23GlobeNewswireU.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome

13.06.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2023

12.06.23GlobeNewswireIpsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023

09.06.23GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06.06.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2023

01.06.23GlobeNewswireIpsen SA initiates a share buy-back program to cover its free employee share-allocation plan

31.05.23GlobeNewswireIpsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023

31.05.23GlobeNewswireIpsen - Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023

26.05.23GlobeNewswireIpsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

17.05.23GlobeNewswireIpsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases

10.05.23GlobeNewswireIpsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital - April 2023

10.05.23GlobeNewswireIpsen : 2023 CSM - Formalities for making available preparatory documents to the Meeting

27.04.23GlobeNewswireIpsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

24.04.23GlobeNewswireIpsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

11.04.23GlobeNewswireIpsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital

06.04.23GlobeNewswireIpsen S.A. publishes its 2022 Universal registration document

16.03.23GlobeNewswireIpsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP

10.03.23GlobeNewswireIpsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital

02.03.23GlobeNewswireIpsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

22.02.23GlobeNewswireIpsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023

15.02.23GlobeNewswireIpsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

13.02.23GlobeNewswireCabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

27.01.23BusinesswireIpsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.

20.01.23BusinesswireIpsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI

Ipsen News

Ipsen News: auf dieser Seite finden Sie alle Ipsen News und Nachrichten zur Ipsen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ipsen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ipsen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.